Viscus Biologics Awarded Biomaterials Commercialisation Licence by National University of Ireland Galway
Tuesday, 30 October 2012
Viscus Biologics LLC, Cleveland, Ohio, has secured an 18-month option to conduct further research into the development and commercialisation of a new tissue repair material developed by the Network of Excellence for Functional Biomaterials (NFB) at National University of Ireland, Galway. Research on the technology is being carried out by Viscus Biologics at its facility in Cleveland, Ohio.
The technology is the result of ongoing research at NFB to develop novel biomaterials for soft tissue repair in reconstructive surgery and chronic wound healing.
The new technology, called cholecyst-derived extracellular matrix (CEM), is derived from a gallbladder from which the native cells have been removed to leave behind a mesh-like collagen structure. This structure may then be stabilised by various chemical techniques. The nano-topography of the CEM makes it ideal for supporting new cell growth while its mechanical properties ensure that it has the strength and elasticity required for tissue repair. Furthermore the CEM is completely reabsorbed by the body over time, making further surgery for its removal unnecessary.
Some of the initial work was funded by Enterprise Ireland and subsequently by Science Foundation Ireland. Viscus Biologics is affiliated with Galway based Proxy Biomedical, Ltd, a leading innovator in the development of next generation medical products using proprietary biomaterials technology.
“We are delighted to enter into this collaboration with NFB and look forward to developing the full potential of the cholecyst technology developed by Professor Pandit,” commented Dr Thomas Neenan, President and CEO of Viscus Biologics. “Our Irish parent company, Proxy Biomedical, Ltd has enjoyed a long a fruitful relationship with National University of Ireland Galway, and we look forward to a similar productive relationship as we bring innovative technology such as the cholocyst platform to the market.”
Viscus Biologics’ products provide surgeons with a variety of innovative surgical products with three-dimensional structures and properties similar to those found in native tissue. The company’s first product ALLOMEMTM (human peritoneal tissue) is currently marketed in the US.
NFB, which was established with funding from SFI under the Strategic Research Cluster Programme, conducts research on biomaterials, developing technologies for use in clinical applications in the fields of orthopaedics, soft-tissue healing and neural and cardiovascular regeneration.
Author: Marketing and Communications Office, NUI Galway
18 July 2016
Global study shows stroke largely preventable